review glp-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read Current Insights, Advantages and Challenges

Personalized care, built around you A lower-dose GLP-1 approach is often chosen by patients seeking a more gradual, personalized path to metabolic balance and appetite regulation

Strength training does not have to be extreme, but it should be consistent and appropriate for the patients age, fitness level, joint health, and medical history

PlexusDx genetic and biomarker insights may help provide context about how your body metabolizes GLP-1 peptides, but consistent medication potency through proper storage is a prerequisite for that personalization to work

Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: A meta-analysis

Soluble fiber slows glucose absorption, preventing the rapid swings that can trigger nausea in GLP-1 users, especially between meals

Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study